⁶⁷Cu-SARbisPSMA is a new PSMA targeting drug labeled with ⁶⁷Cu and developed as therapeutic analogue of ⁶⁴Cu-SARbisPSMA for the treatment of prostate cancer. The first US Phase I/II clinical trial involving both ⁶⁴Cu/⁶⁷Cu-SARbisPSMA Phase I/II trial was initiated in August 2021 and completion is expected by September 2026.

Target/Mechanism: PSMA

Carrier/Ligand: PSMA

Radiation Type: beta electrons (β^–)